Orally administered anti-diabetes drug Teneria (teneligliptin) was approved for manufacture June 29. The drug is suitable for type-2 diabetes when a special diet and exercise treatment, and additional sulphonylurea or thiazolidinedione treatment is not sufficient. The main characteristics of the drug are sustainable glycemic control through once-a-day oral intake and ease of use for patients with low renal excretion rates or impaired renal functions. This DPP4-inhibitor is also purely domestic, as it is developed and produced in Japan, and is based on data collected from Japanese people. (Click Here For More – Japanese Language)
“Teneria: 5th Japanese “Purely Domestic” DPP4-Inhibitor” -medical.nikkeibp.co.jp (7/27/2012)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?